BIRC5 and chronic myelogenous leukemia, BCR-ABL1 positive: In human or murine CML cells, ex vivo treatment with Ym155 decreased Survivin expression, and with Embelin decreased Xiap1, in a dose dependent manner (Supplementary Fig. 1C).